CANCER TYPE
PROCEDURE
AGE TO BEGIN
RISK FOR GENERAL POPULATION *
Pancreatic Neuroendocrine Tumors (PNET)
Lifetime risk
Up to 80%
<0.1%
Other MEN1-associated tumors and cancers
To age 80
Up to 100%
NA
MEN1
Associated Syndrome
Multiple Endocrine Neoplasia Type 1 (MEN Type
Core Cancer Risk(s)
Endocrine Cancer (Most common is tumors of the parathyroid gland)
Inheritance
Autosomal Dominant
Prevalence
Unknown
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Pancreatic Neuroendocrine Tumors (PNET)
Clinical screening for symptoms
10 years
Annually
Biochemical screening
10 years
Annually
Abdominal MRI or multiphasic CT
10 years
Annually
Consider endoscopic ultrasound and/or functional imaging (i.e. PET/CT or PET/MRI)
Individualized
Individualized
Other MEN1-associated tumors and cancers
Multiple screenings recommended, including clinical screening for symptoms, biochemical screening, and imaging with MRI, CT, ultrasound and other methods
Some screenings are recommended to begin as early as age 5
Every 1 to 3 years